Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CIN-107 in Subjects With Renal Impairment
NCT05470725Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of baxdrostat in hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 8 more. Started Jan 2021; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05470725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470725.